Sleepiness and Driving Performances in Adults With Attention-Deficit/ Hyperactivity Disorder (ADHD)

NCT ID: NCT01160874

Last Updated: 2013-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Attention Deficit/ Hyperactivity Disorder (ADHD) is a developmental disorder which affects 3 to 5 % of school age children. This disorder persists in the adulthood for 60 % of subjects. Children with ADHD are sleepier during the day than normal children. However, there is no information concerning the diurnal sleepiness of adults with ADHD and the impact of this sleepiness on their driving capacity. The investigators postulate that the negative impact of ADHD is due to an awakening disorder which adds to the attentional disorder. The aim of this study is to estimate both the sleepiness by a Maintenance Wakefulness Test (MWT) and the capacity to drive in adults with ADHD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of this study is to estimate both the sleepiness by a Maintenance Wakefulness Test (MWT) and the capacity to drive in adults presenting an ADHD. Duration of participation for each patients will be 7 days. Four days after inclusion, patients will have to stop all psychostimulant treatment. Participants will then spend 24 hours (on days 6 and 7) at the "Groupe d'Etudes Neurophysiologie Pharmacologie Sommeil et Sommnolence"(GENPPHASS) in the "Centre Hospitalier Universitaire"(CHU) of Bordeaux. During this time, they will undergo complete polysomnography.The next day, they will perform a Maintenance Wakefulness Test (MWT). A neuropsychological evaluation of one hour will also be done. Finally, a driving test on a simulator will be performed.

Study significance: patients will benefit from an objective exploration of their sleep (with possibly, a sleep disorder discovery) and from a specific treatment. This study will demonstrate the necessity to investigate daytime function (sleepiness and performance) and the sleep quality of patients with ADHD. It will also demonstrate that part of the adults with ADHD handicap is based on an awakening disorder which adds to the attentional disorder.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Disorder With Hyperactivity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Attention Deficit Disorder / Hyperactivity (ADHD) Cognition Sleepiness Driving

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TDA/H

Group Type EXPERIMENTAL

Polysomnography

Intervention Type OTHER

Sleep study monitoring

Maintenance Wakefulness Test

Intervention Type OTHER

Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Neuropsychological evaluation

Intervention Type BEHAVIORAL

Neuropsychological evaluation for cognitive functions study

Driving test on a simulator

Intervention Type OTHER

Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Sleep apnea patient

Group Type OTHER

Maintenance Wakefulness Test

Intervention Type OTHER

Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Driving test on a simulator

Intervention Type OTHER

Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Healthy volunteer

Group Type OTHER

Polysomnography

Intervention Type OTHER

Sleep study monitoring

Maintenance Wakefulness Test

Intervention Type OTHER

Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Neuropsychological evaluation

Intervention Type BEHAVIORAL

Neuropsychological evaluation for cognitive functions study

Driving test on a simulator

Intervention Type OTHER

Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polysomnography

Sleep study monitoring

Intervention Type OTHER

Maintenance Wakefulness Test

Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Intervention Type OTHER

Neuropsychological evaluation

Neuropsychological evaluation for cognitive functions study

Intervention Type BEHAVIORAL

Driving test on a simulator

Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group for ADHD:

* Patients, male or female, aged 18 to 60 years
* Patients who met the criteria for current diagnosis of ADD / ADHD according to DSM IV-TR
* Patients who met the criteria for diagnosis in childhood ADD / ADHD, as assessed by the scale "Conners'Adult ADHD Diagnostic Interview for DSM-IV" (CCACID) (Conners, 1997)
* Patients with a total score ≥ 20 at the CAARS (hetero-questionnaire to 30 items) (Conners, 1997) with at least 6 items of inattention or hyperactivity subscale ≥ 2
* Patients deprived from all psychostimulants for 72 hours
* Having been schooled up to last year of middle school
* Having regular hours of life 3 days before entering the study
* Having a driver's license
* Registered Social Security
* Having given their written informed consent to participate in the study
* Consent free, informed and written, dated and signed by the patient and the investigator before any examination required by the research.

For the apneic group:

* Patients, male or female, aged 18 to 60 years
* Patients with apnea index of apnea / hypopnea\> 10
* Having been schooled up to last year of middle school
* Having regular hours of life 3 days before entering the study
* Having a driver's license
* Registered Social Security
* Having given their written informed consent to participate in the study
* Consent free, informed and written, dated and signed by the patient and the investigator before any examination required by the research

For the control group:

* Participant male or female, aged 18 to 60 years
* Participant not symptomatic of ADHD (total score WURS less than 46 of the 25 questions about ADHD, and at least four more crosses in the boxes shaded the first 6 issues of ASRS)
* Participant with no complaints of sleep, or excessive daytime sleepiness (no item equal to 4 or 5 to BNSQ, except for items 16 and 17 (for snoring) and ESS total score below 11)
* Participant with an AHI \<10 and MPS index \<15 in ambulatory polygraph during the night of selection
* Participant with an AHI \<10 and MPS Index \<15 after overnight polysomnography in the laboratory prior to the day of testing
* Having been schooled until the third class,
* Having regular hours of life 3 days before entering the study,
* Having a driver's license,
* Registered Social Security,
* Having given their written informed consent to participate in the study
* Consent free, informed and written, dated and signed by the participant and the investigator before any examination required by the research.

Exclusion Criteria

* Posted or Night worker,
* Any evolutionary neurological disorders (brain tumour, epilepsy, migraine, brain vascular accident, multiple sclerosis, myoclonus, chorea, neuropathy, muscular dystrophies, myotonic dystrophy),
* Psychiatric comorbidity: current major depressive episode, current hypo obsessive or obsessive episode, schizophrenia,
* Renal Disorders (renal insufficiency, nephrolithiases),
* Endocrine Pathologies (dysthyroid, diabetes),
* Drug addiction
* Alcoholic Dependence during the last 6 months,
* Dependence in the tetra-hydroxy-cannabinol
* Long-term Treatment by benzodiazépines
* Treatment by atomoxétine
* Persons placed under protection of justice
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bordeaux

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anouck AMESTOY, Dr

Role: PRINCIPAL_INVESTIGATOR

University Hospital Bordeaux (France)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Bordeaux

Bordeaux, , France

Site Status

Hôpital Charles Perrens

Bordeaux, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Bioulac S, Chaufton C, Taillard J, Claret A, Sagaspe P, Fabrigoule C, Bouvard MP, Philip P. Excessive daytime sleepiness in adult patients with ADHD as measured by the Maintenance of Wakefulness Test, an electrophysiologic measure. J Clin Psychiatry. 2015 Jul;76(7):943-8. doi: 10.4088/JCP.14m09087.

Reference Type DERIVED
PMID: 25610980 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUBX 2009/17

Identifier Type: -

Identifier Source: org_study_id